Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine

References

• Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol [Internet]. 2009;8(5):475–490. doi:10.1016/S1474-4422(09)70063-8.
   PubMed Web of Science ®Google Scholar
• Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present and future. J Clin Invest. 2006;116(11):2843–2854. doi:10.1172/JCI29894.
   PubMed Web of Science ®Google Scholar
• Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570–2581. doi:10.1056/NEJMra1602678.
   PubMed Web of Science ®Google Scholar
• Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687–693. doi:10.1111/ene.12359.
   PubMed Web of Science ®Google Scholar
• Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012. doi:10.1155/2012/874680:874680. Epub 2012 Oct 31. PMID: 23193443; PMCID: PMC3501798.
   PubMedGoogle Scholar
• Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle and Nerve. 2008;37(2):141–149. doi:10.1002/mus.20950.
   PubMed Web of Science ®Google Scholar
• Rubinstein TJ. Thyroid eye disease following COVID-19 vaccine in a patient with a history graves’ disease: a case report. Ophthal Plast Reconstr Surg. 2021;37(6):e221–3. doi:10.1097/IOP.0000000000002059.
   PubMed Web of Science ®Google Scholar
• Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: a narrative review for clinicians. Rev Neurol (Paris). 2021;177(1–2):51–64. doi:10.1016/j.neurol.2020.10.001.
   PubMed Web of Science ®Google Scholar
• Marx J. Rosen’s Emergency Medicine: Concepts and Clinical Practice. 8th ed. Philadelphia: Elsevier/Saunders; 2014:1441–1444.
   Google Scholar
• Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020;173(12):1027–1028. doi:10.7326/L20-0845.
   PubMed Web of Science ®Google Scholar
• Muppidi S, Guptill JT, Jacob S, Li YL, Farrugia ME, Guidon AC, et al. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol. 2020;19(12):970–971. doi:10.1016/S1474-4422(20)30413-0.
   PubMed Web of Science ®Google Scholar
• Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, et al. COVID-19 in patients with myasthenia gravis. Muscle and Nerve. 2020;62(2):254–258. doi:10.1002/mus.26918.
   PubMed Web of Science ®Google Scholar
• Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendonça RH, Souza PVS, et al. Myasthenia Gravis and COVID-19: clinical characteristics and outcomes. Front Neurol 2020 11(September);11:1053. doi:10.3389/fneur.2020.01053. PMID: 33013676; PMCID: PMC7516054.
   PubMed Web of Science ®Google Scholar
• Chavez A, Pougnier C. A case of COVID-19 vaccine associated new diagnosis myasthenia gravis. J Prim Care Community Heal. 2021;12:19–21.
   Web of Science ®Google Scholar
• Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mrna/dna sars-cov-2 vaccination. Vaccines (Basel). 2021;9(435):1–23. doi:10.3390/vaccines9050435.
   Web of Science ®Google Scholar
• Tagliaferri AR, Narvaneni S, Azzam MH, Grist W. A case of COVID-19 vaccine causing a myasthenia gravis crisis. Cureus. 2021;13:13–15.
   Web of Science ®Google Scholar
• Solé G, Mathis S, Friedman D, Salort-Campana E, Tard C, Bouhour F, et al. Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis. Neurology. 2021;96(16):e2109–20. doi:10.1212/WNL.0000000000011669.
   PubMed Web of Science ®Google Scholar
• Jakubíková M, Týblová M, Tesař A, Horáková M, Vlažná D, Ryšánková I, et al. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021;28(10):3418–3425. doi:10.1111/ene.14951.
   PubMed Web of Science ®Google Scholar
• Sanghani N, Hanumanthu R, Shah S, Souayah N. Myasthenia gravis after vaccination in adults the United States: a Report from the CDC/FDA vaccine adverse event reporting system (1990–2017) (P6.437). Neurology. 2018;90(15).
   Google Scholar
• Zhou Q, Zhou R, Yang H, Yang H. To be or not to be vaccinated: that is a question in myasthenia gravis. Front Immunol. 2021;12:1–15.
   Web of Science ®Google Scholar
• Strijbos E, Huijbers MG, van Es IE, Alleman I, van Ostaijen-ten Dam MM, Bakker J, et al. A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis. Vaccine [Internet]. 2017;35(46):6290–6296. doi:10.1016/j.vaccine.2017.09.078.
   PubMed Web of Science ®Google Scholar
• Strijbos E, Tannemaat MR, Alleman I, de Meel RHP, Bakker JA, van Beek R, et al. A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine [Internet]. 2019;37(7):919–925. doi:10.1016/j.vaccine.2019.01.007.
   PubMed Web of Science ®Google Scholar
• Ruan Z, Tang Y, Li C, Sun C, Zhu Y, Li Z, et al. COVID-19 vaccination in patients with myasthenia gravis : a single-center case series. Vaccines. 2021;9(10):1112. doi:10.3390/vaccines9101112.
   Web of Science ®Google Scholar
• Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol [Internet]. 2021;21(4):195–197. doi:10.1038/s41577-021-00526-x.
   PubMed Web of Science ®Google Scholar
• Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;362(9396):1659–1666. doi:10.1016/S0140-6736(03)14802-7.
   PubMed Web of Science ®Google Scholar
• Salehen N, Stover C. The role of complement in the success of vaccination with conjugated vs. unconjugated polysaccharide antigen. Vaccine. 2008;26(4):451–459. doi:10.1016/j.vaccine.2007.11.049.
   PubMed Web of Science ®Google Scholar
• Kurtovic L, Beeson JG. Complement factors in COVID-19 therapeutics and vaccines. Trends Immunol. 2021;42(2):94–103. doi:10.1016/j.it.2020.12.002.
   PubMed Web of Science ®Google Scholar
• Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22(2):77–84. doi:10.1038/s41577-021-00665-1.
   PubMed Web of Science ®Google Scholar
• Howard JF. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113–128. doi:10.1111/nyas.13522.
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID-19 Vaccines :Safety Surveillance Manual Module : Responding to Adverse Events. Geneva: World Health Organization; 2020.
   Google Scholar